Health industries dealmakers are starting 2026 with renewed confidence and strategic urgency. After two years of navigating macroeconomic volatility and regulatory uncertainty, PwC sees acceleration, rather than stabilisation, defining the M&A environment. Investors are entering 2026 with a renewed appetite for deals. Last year’s activity was shaped by the M&A “triple threat” of tariffs, drug pricing pressures, and regulatory shifts—conditions that steered buyers towards targeted transactions, such as those that filled critical pipeline gaps. As 2026 unfolds, leading health industries players are making bolder moves that reposition portfolios for a future in which every part of the healthcare value chain, from drug discovery to care delivery, is being redefined.
Read the full article: PwC 2026 Outlook: Global M&A Trends in Health Industries //
Source: https://www.pwc.com/gx/en/services/deals/trends/health-industries.html